Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:CASNumber |
1513858-77-6
|
| gptkbp:chemicalFormula |
C24H27F2N5O2
|
| gptkbp:developer |
gptkb:Incyte_Corporation
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:genericName |
gptkb:pemigatinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pemazyre
|
| gptkbp:indication |
unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue alopecia dry mouth hyperphosphatemia nail toxicity stomatitis |
| gptkbp:usedFor |
cholangiocarcinoma
myeloid/lymphoid neoplasms with FGFR1 rearrangement |
| gptkbp:bfsParent |
gptkb:Incyte
|
| gptkbp:bfsLayer |
6
|